Key terms
About XFOR
X4 Pharmaceuticals, Inc. is a late clinical-stage company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. Its clinical candidate is mavorixafor. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest XFOR news
Apr 01
9:32am ET
X4 Pharmaceuticals Updates Corporate Presentation Online
Mar 23
2:01am ET
X4 Pharmaceuticals on the Brink: The Race Against Nasdaq Delisting and Investor Confidence
Mar 22
6:28am ET
Buy Rating Affirmed on X4 Pharmaceuticals Amid Positive Mavorixafor Prospects
Mar 21
6:02am ET
X4 Pharmaceuticals reports Q4 EPS (10c), consensus (15c)
Mar 18
8:00am ET
Options Volatility and Implied Earnings Moves This Week, March 18 – March 21, 2024
Feb 29
10:32am ET
X4 Pharmaceuticals management to meet with Cantor Fitzgerald
No recent press releases are available for XFOR
XFOR Financials
Key terms
Ad Feedback
XFOR Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
XFOR Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
